In this free webinar, the speakers will give an overview of the role of Tau in disease progression and discuss the importance of Tau PET imaging in clinical trials and the challenges of implementing it. They will also report on recent research addressing the optimization of Tau PET analysis methodologies.
TORONTO (PRWEB) April 07, 2020
Join Victor L. Villemagne, Associate Professor, Department of Molecular Imaging and Therapy, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne and Richard Manber, Biomarker Scientist, IXICO in a live webinar on Friday, April 24, 2020 at 10am EDT (3pm BST/UK).
In recent years, there has been an increasing focus on investigating the role of Tau in the onset and progression of Alzheimer’s Disease (AD), and in other neurodegenerative diseases associated with the accumulation of pathological misfolded Tau, such as progressive supranuclear palsy (PSP) and frontotemporal lobar degeneration (FTLD). Studies using recently introduced second-generation Tau tracers suggests that these tracers are binding to Tau with higher specificity compared to previous tracers, leading to increased interest in Tau within clinical studies. However, it’s still unclear what role Tau imaging will play in clinical trials: should Tau be used as a clinical endpoint; and how does it link to other biomarkers such as amyloid-beta, with some studies suggesting that amyloid-beta triggers the spread of Tau beyond the MTL region.
Given that the majority of Tau studies have been conducted using first-generation PET tracers, which had shown high incidences of off-site binding, it will be important to review the current data to understand what we know about Tau in AD and how second-generation tracers are being applied in clinical studies. Additionally, this webinar will cover the steps being taken to advance Tau PET operational and analytical methodologies in AD clinical studies and other Tau-related neurodegenerative diseases.
For more information or to register for this event, visit Optimization of Tau PET Imaging for Alzheimer’s Clinical Development.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
For the original version on PRWeb visit: https://www.prweb.com/releases/optimization_of_tau_pet_imaging_for_alzheimers_clinical_development_upcoming_webinar_hosted_by_xtalks/prweb17031578.htm